Abstract
Mimetics of the anorexigenic gut hormone glucagon-like peptide 1 (GLP-1) were originally developed as insulinotropic anti-diabetic drugs but also evoke significant weight loss, leading to their recent approval as obesity therapeutics. Co-activation of receptors for GLP-1 and other gut hormones which reduce food intake – peptide YY (PYY3–36), cholecystokinin (CCK) and glucose-dependent insulinotropic peptide (GIP) – is now being explored clinically to enhance efficacy. An alternative approach involves pharmacologically stimulating endogenous secretion of these hormones from enteroendocrine cells (EECs) to recapitulate the metabolic consequences of bariatric surgery, where highly elevated postprandial levels of GLP-1 and PYY3–36 are thought to contribute to improved glycaemia and weight loss.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aaboe K, Knop FK, Vilsboll T, Deacon CF, Holst JJ, Madsbad S, Krarup T (2010) Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 12:323–333. https://doi.org/10.1111/j.1463-1326.2009.01167.x
Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, Polex-Wolf J, Lam BY, Zvetkova I, Pan W, Chiarugi D, Yeo GSH, Blouet C, Gribble FM, Reimann F (2019) Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab 30:987–996.e6. https://doi.org/10.1016/j.cmet.2019.07.013
Adrian TE, Gariballa S, Parekh KA, Thomas SA, Saadi H, Al Kaabi J, Nagelkerke N, Gedulin B, Young AA (2012) Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 55:2343–2347. https://doi.org/10.1007/s00125-012-2593-2
Ambery PD, Klammt S, Posch MG, Petrone M, Pu W, Rondinone C, Jermutus L, Hirshberg B (2018) MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, phase 1 study. Br J Clin Pharmacol 84:2325–2335. https://doi.org/10.1111/bcp.13688
Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C (2007) Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 92:2977–2983. https://doi.org/10.1210/jc.2006-2003
Bala V, Rajagopal S, Kumar DP, Nalli AD, Mahavadi S, Sanyal AJ, Grider JR, Murthy KS (2014) Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-epsilon pathway and modulated by endogenous H2S. Front Physiol 5:420. https://doi.org/10.3389/fphys.2014.00420
Ballantyne GH (2006) Peptide YY(1-36) and peptide YY(3-36): part I. distribution, release and actions. Obes Surg 16:651–658. https://doi.org/10.1381/096089206776944959
Bays HE (2011) Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies. Endocr Pract 17:933–938. https://doi.org/10.4158/EP11218.OR
Behary P, Tharakan G, Alexiadou K, Johnson N, Wewer Albrechtsen NJ, Kenkre J, Cuenco J, Hope D, Anyiam O, Choudhury S, Alessimii H, Poddar A, Minnion J, Doyle C, Frost G, Le Roux C, Purkayastha S, Moorthy K, Dhillo W, Holst JJ, Ahmed AR, Prevost AT, Bloom SR, Tan TM (2019) Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized, single-blinded, placebo-controlled study. Diabetes Care 42:1446–1453. https://doi.org/10.2337/dc19-0449
Beumer J, Artegiani B, Post Y, Reimann F, Gribble F, Nguyen TN, Zeng H, Van den Born M, Van Es JH, Clevers H (2018) Enteroendocrine cells switch hormone expression along the crypt-to-villus BMP signalling gradient. Nat Cell Biol 20(8):909–916
Beumer J, Puschhof J, Bauza-Martinez J, Martinez-Silgado A, Elmentaite R, James KR, Ross A, Hendriks D, Artegiani B, Busslinger GA, Ponsioen B, Andersson-Rolf A, Saftien A, Boot C, Kretzschmar K, Geurts MH, Bar-Ephraim YE, Pleguezuelos-Manzano C, Post Y, Begthel H, van der Linden F, Lopez-Iglesias C, van de Wetering WJ, van der Linden R, Peters PJ, Heck AJR, Goedhart J, Snippert H, Zilbauer M, Teichmann SA, Wu W, Clevers H (2020) High-resolution mRNA and secretome atlas of human enteroendocrine cells. Cell 181(6):1291–1306.e19. https://doi.org/10.1016/j.cell.2020.04.036
Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, Turner SM, Protasio J, Riiff T, Hellerstein MK (2012) Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 55:432–442. https://doi.org/10.1007/s00125-011-2382-3
Billing LJ, Larraufie P, Lewis J, Leiter A, Li J, Lam B, Yeo GS, Goldspink DA, Kay RG, Gribble FM, Reimann F (2019) Single cell transcriptomic profiling of large intestinal enteroendocrine cells in mice – identification of selective stimuli for insulin-like peptide-5 and glucagon-like peptide-1 co-expressing cells. Mol Metab 29:158–169. https://doi.org/10.1016/j.molmet.2019.09.001
Boehringer Ingelheim (2019) Boehringer Ingelheim and Zealand pharma advance dual-acting GLP-1/glucagon agonist BI 456906 to phase 2 clinical testing in obesity/diabetes
Boland BB, Mumphrey MB, Hao Z, Townsend RL, Gill B, Oldham S, Will S, Morrison CD, Yu S, Munzberg H, Rhodes CJ, Trevaskis JL, Berthoud HR (2019) Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice. Mol Metab 25:64–72. https://doi.org/10.1016/j.molmet.2019.05.004
Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, Lewis H, Conway J, Naylor J, Guionaud S, Feigh M, Veidal SS, Lantier L, McGuinness OP, Grimsby J, Rondinone CM, Jermutus L, Larsen MR, Trevaskis JL, Rhodes CJ (2020) Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab 2:413–431. https://doi.org/10.1038/s42255-020-0209-6
Boyle CN, Lutz TA, Le Foll C (2018) Amylin – its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab 8:203–210. https://doi.org/10.1016/j.molmet.2017.11.009
Brandt SJ, Gotz A, Tschop MH, Muller TD (2018) Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides 100:190–201. https://doi.org/10.1016/j.peptides.2017.12.021
Briere DA, Bueno AB, Gunn EJ, Michael MD, Sloop KW (2018) Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery. Diabetes 67:309–320. https://doi.org/10.2337/db17-0607
Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ, Gribble FM, Reimann F (2015) Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein–coupled bile acid receptors. Endocrinology 156:3961–3970. https://doi.org/10.1210/en.2015-1321
Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, Minnick DT, Murdock PR, Sauls HR Jr, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, Ignar DM, Wilson S, Muir AI (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278:11303–11311. https://doi.org/10.1074/jbc.M211495200
Brown SP, Dransfield P, Vimolratana M, Zhu L, Luo J, Zhang J, Jiao X, Pattaropong V, Wong S, Zhuang R, Swaminath G, Houze JB, Lin DC (2018) Discovery of AM-6226: a potent and orally bioavailable GPR40 full agonist that displays efficacy in nonhuman primates. ACS Med Chem Lett 9:757–760. https://doi.org/10.1021/acsmedchemlett.8b00213
Brufau G, Stellaard F, Prado K, Bloks VW, Jonkers E, Boverhof R, Kuipers F, Murphy EJ (2010) Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52:1455–1464. https://doi.org/10.1002/hep.23831
Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, Leifke E (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379:1403–1411. https://doi.org/10.1016/S0140-6736(11)61879-5
Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M (2005) A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 27:210–215. https://doi.org/10.1016/j.clinthera.2005.02.008
Calderon G, McRae A, Rievaj J, Davis J, Zandvakili I, Linker-Nord S, Burton D, Roberts G, Reimann F, Gedulin B, Vella A, LaRusso NF, Camilleri M, Gribble FM, Acosta A (2020) Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. EBioMedicine 55:102759. https://doi.org/10.1016/j.ebiom.2020.102759
Cawston EE, Miller LJ (2010) Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br J Pharmacol 159:1009–1021. https://doi.org/10.1111/j.1476-5381.2009.00489.x
Chen L, Yao X, Young A, McNulty J, Anderson D, Liu Y, Nystrom C, Croom D, Ross S, Collins J, Rajpal D, Hamlet K, Smith C, Gedulin B (2012) Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab 302:E68–E76. https://doi.org/10.1152/ajpendo.00323.2011
Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, Melvin DL, Egan JM (2009) Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58:1342–1349. https://doi.org/10.2337/db08-0958
Christensen LW, Kuhre RE, Janus C, Svendsen B, Holst JJ (2015) Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine. Physiol Rep 3:e12551. https://doi.org/10.14814/phy2.12551
Christoffersen BO, Skyggebjerg RB, Bugge A, Kirk RK, Vestergaard B, Uldam HK, Fels JJ, Pyke C, Sensfuss U, Sanfridson A, Clausen TR (2020) Long-acting CCK analogue NN9056 lowers food intake and body weight in obese Gottingen Minipigs. Int J Obes 44:447–456. https://doi.org/10.1038/s41366-019-0386-0
Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, Lucman A, Moloney M, Gao H, Mondala H, Bagnol D, Unett D, Liang Y, Demarest K, Semple G, Behan DP, Leonard J (2007) A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148:2601–2609. https://doi.org/10.1210/en.2006-1608
Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R, Jones RM, Behan DP, Leonard J (2008) A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149:2038–2047. https://doi.org/10.1210/en.2007-0966
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 18:3–14. https://doi.org/10.1016/j.molmet.2018.09.009
CymaBay (2020) CymaBay announces study to evaluate the potential for GPR119 agonists to prevent hypoglycemia in type 1 diabetes. https://www.globenewswire.com/en/news-release/2020/11/05/2120994/37067/en/CymaBay-Announces-Study-to-Evaluate-the-Potential-for-GPR119-Agonists-to-Prevent-Hypoglycemia-in-Type-1-Diabetes.html. Accessed 1 Jun 2021
Darwich AS, Aslam U, Ashcroft DM, Rostami-Hodjegan A (2014) Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. Drug Metab Dispos 42:2016–2022. https://doi.org/10.1124/dmd.114.058404
Dawson PA, Lan T, Rao A (2009) Bile acid transporters. J Lipid Res 50:2340–2357. https://doi.org/10.1194/jlr.R900012-JLR200
De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, Ghatei MA, Bloom SR, Matthews PM, Beaver JD, Dhillo WS (2011) The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 14:700–706. https://doi.org/10.1016/j.cmet.2011.09.010
Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705. https://doi.org/10.1016/S0140-6736(06)69705-5
Edfalk S, Steneberg P, Edlund H (2008) Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57:2280–2287. https://doi.org/10.2337/db08-0307
Ellrichmann M, Kapelle M, Ritter PR, Holst JJ, Herzig KH, Schmidt WE, Schmitz F, Meier JJ (2008) Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab 93:3995–3998. https://doi.org/10.1210/jc.2008-0924
Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 397:1736–1748. https://doi.org/10.1016/S0140-6736(21)00845-X
Farb TB, Adeva M, Beauchamp TJ, Cabrera O, Coates DA, Meredith TD, Droz BA, Efanov A, Ficorilli JV, Gackenheimer SL, Martinez-Grau MA, Molero V, Ruano G, Statnick MA, Suter TM, Syed SK, Toledo MA, Willard FS, Zhou X, Bokvist KB, Barrett DG (2017) Regulation of endogenous (male) rodent GLP-1 secretion and human islet insulin secretion by antagonism of somatostatin receptor 5. Endocrinology 158:3859–3873. https://doi.org/10.1210/en.2017-00639
Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschop MH (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5:209ra151. https://doi.org/10.1126/scitranslmed.3007218
Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, Riboulet W, Funk J, Hertel C, Belli S, Sebokova E, Conde-Knape K, Konkar A, Drucker DJ, Gelfanov V, Pfluger PT, Muller TD, Perez-Tilve D, DiMarchi RD, Tschop MH (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27–36. https://doi.org/10.1038/nm.3761
Fletcher MM, Keov P, Truong TT, Mennen G, Hick CA, Zhao P, Furness SGB, Kruse T, Clausen TR, Wootten D, Sexton PM (2021) AM833 is a novel agonist of calcitonin family G protein-coupled receptors: pharmacological comparison with six selective and nonselective agonists. J Pharmacol Exp Ther 377:417–440. https://doi.org/10.1124/jpet.121.000567
Flock G, Holland D, Seino Y, Drucker DJ (2011) GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 152:374–383. https://doi.org/10.1210/en.2010-1047
Frias JP, Bastyr EJ 3rd, Vignati L, Tschop MH, Schmitt C, Owen K, Christensen RH, DiMarchi RD (2017) The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 26:343–352.e2. https://doi.org/10.1016/j.cmet.2017.07.011
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392:2180–2193. https://doi.org/10.1016/S0140-6736(18)32260-8
Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K, Stevens C, Stroh MA, Zhu H, Wagner JA, Macneil DJ, Heymsfield SB, Amatruda JM (2007) Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 92:1754–1757. https://doi.org/10.1210/jc.2006-1806
Gehart H, van Es JH, Hamer K, Beumer J, Kretzschmar K, Dekkers JF, Rios A, Clevers H (2019) Identification of enteroendocrine regulators by real-time single-cell differentiation mapping. Cell 176:1158–1173.e16. https://doi.org/10.1016/j.cell.2018.12.029
Goldspink DA, Lu VB, Miedzybrodzka EL, Smith CA, Foreman RE, Billing LJ, Kay RG, Reimann F, Gribble FM (2020) Labeling and characterization of human GLP-1-secreting L-cells in primary ileal organoid culture. Cell Rep 31:107833. https://doi.org/10.1016/j.celrep.2020.107833
Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, Reimann F, Holst JJ, Gribble FM (2009) Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 89:106–113. https://doi.org/10.3945/ajcn.2008.26362
Habegger KM, Stemmer K, Cheng C, Muller TD, Heppner KM, Ottaway N, Holland J, Hembree JL, Smiley D, Gelfanov V, Krishna R, Arafat AM, Konkar A, Belli S, Kapps M, Woods SC, Hofmann SM, D'Alessio D, Pfluger PT, Perez-Tilve D, Seeley RJ, Konishi M, Itoh N, Kharitonenkov A, Spranger J, DiMarchi RD, Tschop MH (2013) Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62:1453–1463. https://doi.org/10.2337/db12-1116
Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CAM, Parker HE, Morley TCE, Yeo GSH, Reimann F, Gribble FM (2012) Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153:3054–3065. https://doi.org/10.1210/en.2011-2170
Hanmi (2020) Study to evaluate efficacy, safety and tolerability of HM15211 in subjects. https://clinicaltrials.gov/ct2/show/NCT04505436. Accessed 3 Jun 2021
Hansen KB, Rosenkilde MM, Knop FK, Wellner N, Diep TA, Rehfeld JF, Andersen UB, Holst JJ, Hansen HS (2011) 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab 96:E1409–E1417. https://doi.org/10.1210/jc.2011-0647
Hansen M, Scheltema MJ, Sonne DP, Hansen JS, Sperling M, Rehfeld JF, Holst JJ, Vilsboll T, Knop FK (2016) Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes Metab 18:571–580. https://doi.org/10.1111/dom.12648
Hansen HH, Gronlund RV, Baader-Pagler T, Haebel P, Tammen H, Larsen LK, Jelsing J, Vrang N, Klein T (2021) Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice. Sci Rep 11:8060. https://doi.org/10.1038/s41598-021-87539-7
Hay DL, Garelja ML, Poyner DR, Walker CS (2018) Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. Br J Pharmacol 175:3–17. https://doi.org/10.1111/bph.14075
Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-Lofmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP (2016) Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab 18:1176–1190. https://doi.org/10.1111/dom.12735
Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90–94. https://doi.org/10.1038/nm1168
Hirose H, Yamasaki T, Ogino M, Mizojiri R, Tamura-Okano Y, Yashiro H, Muraki Y, Nakano Y, Sugama J, Hata A, Iwasaki S, Watanabe M, Maekawa T, Kasai S (2017) Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus. Bioorg Med Chem 25:4175–4193. https://doi.org/10.1016/j.bmc.2017.06.007
Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ, Team SBP (2013) Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes. Clin Pharmacol Drug Dev 2:213–222. https://doi.org/10.1002/cpdd.34
Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S (2009) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:199–207. https://doi.org/10.1007/s00125-008-1195-5
Holst JJ, Madsbad S, Bojsen-Moller KN, Svane MS, Jorgensen NB, Dirksen C, Martinussen C (2018) Mechanisms in bariatric surgery: gut hormones, diabetes resolution, and weight loss. Surg Obes Relat Dis 14:708–714. https://doi.org/10.1016/j.soard.2018.03.003
Hornigold DC, Roth E, Howard V, Will S, Oldham S, Coghlan MP, Blouet C, Trevaskis JL (2018) A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice. Appetite 127:334–340. https://doi.org/10.1016/j.appet.2018.05.131
Hucking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA (2005) Alpha-glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in type 2 diabetic patients. Diabet Med 22:470–476. https://doi.org/10.1111/j.1464-5491.2005.01451.x
Irwin N, Pathak V, Flatt PR (2015) A novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat-fed mice. Diabetes 64:2996–3009. https://doi.org/10.2337/db15-0220
Itoh Y, Hinuma S (2005) GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. Hepatol Res 33:171–173. https://doi.org/10.1016/j.hepres.2005.09.028
Jain MR, Giri SR, Trivedi CJ, Bhoi BB, Rath AC, Rathod RM, Sundar R, Bandyopadhyay D, Ramdhave R, Patel GD, Srivastava BK, Desai RC (2018) ZYDG2, a potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes. Diabetes 67. https://doi.org/10.2337/db18-1194-P
Jepsen SL, Grunddal KV, Wewer Albrechtsen NJ, Engelstoft MS, Gabe MBN, Jensen EP, Orskov C, Poulsen SS, Rosenkilde MM, Pedersen J, Gribble FM, Reimann F, Deacon CF, Schwartz TW, Christ AD, Martin RE, Holst JJ (2019) Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice. Am J Physiol Endocrinol Metab 317:E1081–E1093. https://doi.org/10.1152/ajpendo.00239.2019
Jepsen SL, Albrechtsen NJW, Windelov JA, Galsgaard KD, Hunt JE, Farb TB, Kissow H, Pedersen J, Deacon CF, Martin RE, Holst JJ (2021) Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner. JCI Insight 6. https://doi.org/10.1172/jci.insight.143228
Jonsson I, Bojsen-Moller KN, Kristiansen VB, Veedfald S, Wewer Albrechtsen NJ, Clausen TR, Kuhre RE, Rehfeld JF, Holst JJ, Madsbad S, Svane MS (2021) Effects of manipulating circulating bile acid concentrations on postprandial GLP-1 secretion and glucose metabolism after Roux-en-Y gastric bypass. Front Endocrinol (Lausanne) 12:681116. https://doi.org/10.3389/fendo.2021.681116
Jordan J, Greenway FL, Leiter LA, Li Z, Jacobson P, Murphy K, Hill J, Kler L, Aftring RP (2008) Stimulation of cholecystokinin-a receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 83:281–287. https://doi.org/10.1038/sj.clpt.6100272
Jorgensen NB, Dirksen C, Bojsen-Moller KN, Jacobsen SH, Worm D, Hansen DL, Kristiansen VB, Naver L, Madsbad S, Holst JJ (2013) Exaggerated glucagon-like peptide 1 response is important for improved beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62:3044–3052. https://doi.org/10.2337/db13-0022
Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R (2016) Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. Diabetes Obes Metab 18:925–929. https://doi.org/10.1111/dom.12693
Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil DJ, Van der Ploeg LH, Saga Y, Nishimura S, Ihara M (2000) Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 141:1011–1016. https://doi.org/10.1210/endo.141.3.7387
Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L, Sarich TC, Stein PP (2012) Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab 14:709–716. https://doi.org/10.1111/j.1463-1326.2012.01587.x
Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X, Komorowski R, Hager T, Deng L, Atangan L, Lu SC, Kurzeja RJM, Sivits G, Lin J, Chen Q, Wang Z, Thibault SA, Abbott CM, Meng T, Clavette B, Murawsky CM, Foltz IN, Rottman JB, Hale C, Veniant MM, Lloyd DJ (2018) Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med 10. https://doi.org/10.1126/scitranslmed.aat3392
Killion EA, Lu SC, Fort M, Yamada Y, Veniant MM, Lloyd DJ (2020) Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists = antagonists? Endocr Rev 41. https://doi.org/10.1210/endrev/bnz002
Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L, Petrie MC, McMurray JJV (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776–785. https://doi.org/10.1016/S2213-8587(19)30249-9
Kuhre RE, Wewer Albrechtsen NJ, Larsen O, Jepsen SL, Balk-Moller E, Andersen DB, Deacon CF, Schoonjans K, Reimann F, Gribble FM, Albrechtsen R, Hartmann B, Rosenkilde MM, Holst JJ (2018) Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Mol Metab 11:84–95. https://doi.org/10.1016/j.molmet.2018.03.007
Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B (2007) Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709–1716. https://doi.org/10.2337/dc06-1549
Larraufie P, Roberts GP, McGavigan AK, Kay RG, Li J, Leiter A, Melvin A, Biggs EK, Ravn P, Davy K, Hornigold DC, Yeo GSH, Hardwick RH, Reimann F, Gribble FM (2019) Important role of the GLP-1 axis for glucose homeostasis after bariatric surgery. Cell Rep 26:1399–1408.e6. https://doi.org/10.1016/j.celrep.2019.01.047
Lear S, Pflimlin E, Zhou Z, Huang D, Weng S, Nguyen-Tran V, Joseph SB, Roller S, Peterson S, Li J, Tremblay M, Schultz PG, Shen W (2020) Engineering of a potent, long-acting NPY2R agonist for combination with a GLP-1R agonist as a multi-hormonal treatment for obesity. J Med Chem 63:9660–9671. https://doi.org/10.1021/acs.jmedchem.0c00740
Lewis JE, Miedzybrodzka EL, Foreman RE, Woodward ORM, Kay RG, Goldspink DA, Gribble FM, Reimann F (2020) Selective stimulation of colonic L cells improves metabolic outcomes in mice. Diabetologia. https://doi.org/10.1007/s00125-020-05149-w
Lexicon (2018) Lexicon Pharmaceuticals announces topline phase 1 clinical results for LX2761 in diabetes. https://www.lexpharma.com/media-center/news/693-lexicon-pharmaceuticals-announces-topline-phase-1-clinical-results-for-lx2761-in-diabetes. Accessed 4 Jun 2021
Li Z, Kelly L, Heiman M, Greengard P, Friedman JM (2015) Hypothalamic amylin acts in concert with leptin to regulate food intake. Cell Metab 22:1059–1067. https://doi.org/10.1016/j.cmet.2015.10.012
Lilly (2021) Medicines in development. https://www.lilly.com/discovery/clinical-development-pipeline. Accessed 1 Jun 2021
Lin HV, Efanov AM, Fang X, Beavers LS, Wang X, Wang J, Gonzalez Valcarcel IC, Ma T (2016) GPR142 controls tryptophan-induced insulin and incretin hormone secretion to improve glucose metabolism. PLoS One 11:e0157298. https://doi.org/10.1371/journal.pone.0157298
Lund ML, Sorrentino G, Egerod KL, Kroone C, Mortensen B, Knop FK, Reimann F, Gribble FM, Drucker DJ, de Koning EJP, Schoonjans K, Backhed F, Schwartz TW, Petersen N (2020) L-cell differentiation is induced by bile acids through GPBAR1 and paracrine GLP-1 and serotonin signaling. Diabetes 69:614–623. https://doi.org/10.2337/db19-0764
Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, Chen M, Nguyen K, Tran T, Miao L, Dransfield PJ, Vimolratana M, Houze JB, Wong S, Toteva M, Shan B, Li F, Zhuang R, Lin DC (2012) A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One 7:e46300. https://doi.org/10.1371/journal.pone.0046300
Ma J, Checklin HL, Wishart JM, Stevens JE, Jones KL, Horowitz M, Meyer JH, Rayner CK (2013) A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetes. Diabetologia 56:1236–1242. https://doi.org/10.1007/s00125-013-2876-2
Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, de Las FL, He S, Okunade AL, Patterson BW, Klein S (2016) Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 23:591–601. https://doi.org/10.1016/j.cmet.2016.02.005
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, SUSTAIN-6 Investigators (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844. https://doi.org/10.1056/NEJMoa1607141
McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ (2021) Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev 42:101–132. https://doi.org/10.1210/endrev/bnaa032
Meek CL, Lewis HB, Vergese B, Park A, Reimann F, Gribble F (2016) The effect of encapsulated glutamine on gut peptide secretion in human volunteers. Peptides 77:38–46. https://doi.org/10.1016/j.peptides.2015.10.008
Mehta A, Marso SP, Neeland IJ (2017) Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract 3:3–14. https://doi.org/10.1002/osp4.84
Mekhjian HS, Phillips SF, Hofmann AF (1979) Colonic absorption of unconjugated bile acids: perfusion studies in man. Dig Dis Sci 24:545–550. https://doi.org/10.1007/BF01489324
Meyer-Gerspach AC, Steinert RE, Keller S, Malarski A, Schulte FH, Beglinger C (2013) Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans. J Clin Endocrinol Metab 98:3351–3358. https://doi.org/10.1210/jc.2012-4109
Moss CE, Marsh WJ, Parker HE, Ogunnowo-Bada E, Riches CH, Habib AM, Evans ML, Gribble FM, Reimann F (2012) Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia 55:3094–3103. https://doi.org/10.1007/s00125-012-2663-5
Moss CE, Glass LL, Diakogiannaki E, Pais R, Lenaghan C, Smith DM, Wedin M, Bohlooly-Y M, Gribble FM, Reimann F (2016) Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells. Peptides 77:16–20. https://doi.org/10.1016/J.PEPTIDES.2015.06.012
Mroz PA, Finan B, Gelfanov V, Yang B, Tschop MH, DiMarchi RD, Perez-Tilve D (2019) Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metab 20:51–62. https://doi.org/10.1016/j.molmet.2018.12.001
Mulvihill EE, Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35:992–1019. https://doi.org/10.1210/er.2014-1035
Mumphrey MB, Patterson LM, Zheng H, Berthoud HR (2013) Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats. Neurogastroenterol Motil 25:e70–e79. https://doi.org/10.1111/nmo.12034
Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, Hirshberg B, Ambery P (2021) Effects of Cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care. https://doi.org/10.2337/dc20-2151
Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y (2012) Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 14:283–287. https://doi.org/10.1111/j.1463-1326.2011.01526.x
Naslund E, Gryback P, Hellstrom PM, Jacobsson H, Holst JJ, Theodorsson E, Backman L (1997) Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21:387–392. https://doi.org/10.1038/sj.ijo.0800418
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307. https://doi.org/10.1172/JCI116186
Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR (2005) Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146:5120–5127. https://doi.org/10.1210/en.2005-0237
Novo Nordisk (2019) Research study of a new medicine (NNC9204-1706) in people with overweight or obesity. https://clinicaltrials.gov/ct2/show/NCT03661879. Accessed 4 Jun 2021
Nunez DJ, Bush MA, Collins DA, McMullen SL, Gillmor D, Apseloff G, Atiee G, Corsino L, Morrow L, Feldman PL (2014) Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. PLoS One 9:e92494. https://doi.org/10.1371/journal.pone.0092494
Nunez DJ, Yao X, Lin J, Walker A, Zuo P, Webster L, Krug-Gourley S, Zamek-Gliszczynski MJ, Gillmor DS, Johnson SL (2016) Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin. Diabetes Obes Metab 18:654–662. https://doi.org/10.1111/dom.12656
Otieno MA, Snoeys J, Lam W, Ghosh A, Player MR, Pocai A, Salter R, Simic D, Skaggs H, Singh B, Lim HK (2018) Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury. Toxicol Sci 163:374–384. https://doi.org/10.1093/toxsci/kfx040
Pais R, Gribble FM, Reimann F (2016) Signalling pathways involved in the detection of peptones by murine small intestinal enteroendocrine L-cells. Peptides 77:9–15. https://doi.org/10.1016/J.PEPTIDES.2015.07.019
Parker HE, Adriaenssens A, Rogers G, Richards P, Koepsell H, Reimann F, Gribble FM (2012a) Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia 55:2445–2455. https://doi.org/10.1007/s00125-012-2585-2
Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F, Gribble FM (2012b) Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 165:414–423. https://doi.org/10.1111/j.1476-5381.2011.01561.x
Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, Kern B, von Fluee M, Beglinger C (2012) Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 22:740–748. https://doi.org/10.1007/s11695-012-0622-3
Petersen N, Reimann F, Bartfeld S, Farin HF, Ringnalda FC, Vries RG, van den Brink S, Clevers H, Gribble FM, de Koning EJ (2014) Generation of L cells in mouse and human small intestine organoids. Diabetes 63:410–420. https://doi.org/10.2337/db13-0991
Petersen N, Reimann F, van Es JH, van den Berg BM, Kroone C, Pais R, Jansen E, Clevers H, Gribble FM, de Koning EJ (2015) Targeting development of incretin-producing cells increases insulin secretion. J Clin Invest 125:379–385. https://doi.org/10.1172/JCI75838
Petersen N, Frimurer TM, Terndrup Pedersen M, Egerod KL, Wewer Albrechtsen NJ, Holst JJ, Grapin-Botton A, Jensen KB, Schwartz TW (2018) Inhibiting RHOA signaling in mice increases glucose tolerance and numbers of enteroendocrine and other secretory cells in the intestine. Gastroenterology 155:1164–1176.e2. https://doi.org/10.1053/j.gastro.2018.06.039
Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, Kliewer SA, Burgess SC (2013) Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol 304:G371–G380. https://doi.org/10.1152/ajpgi.00400.2012
Powell DR, Smith MG, Doree DD, Harris AL, Greer J, DaCosta CM, Thompson A, Jeter-Jones S, Xiong W, Carson KG, Goodwin NC, Harrison BA, Rawlins DB, Strobel ED, Gopinathan S, Wilson A, Mseeh F, Zambrowicz B, Ding ZM (2017) LX2761, a sodium/glucose cotransporter 1 inhibitor restricted to the intestine, improves glycemic control in mice. J Pharmacol Exp Ther 362:85–97. https://doi.org/10.1124/jpet.117.240820
Rangwala SM, D'Aquino K, Zhang YM, Bader L, Edwards W, Zheng S, Eckardt A, Lacombe A, Pick R, Moreno V, Kang L, Jian W, Arnoult E, Case M, Jenkinson C, Chi E, Swanson RV, Kievit P, Grove K, Macielag M, Erion MD, SinhaRoy R, Leonard JN (2019) A long-acting PYY3-36 analog mediates robust anorectic efficacy with minimal emesis in nonhuman primates. Cell Metab 29:837–843.e5. https://doi.org/10.1016/j.cmet.2019.01.017
Rao A, Kosters A, Mells JE, Zhang W, Setchell KD, Amanso AM, Wynn GM, Xu T, Keller BT, Yin H, Banton S, Jones DP, Wu H, Dawson PA, Karpen SJ (2016) Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med 8:357ra122. https://doi.org/10.1126/scitranslmed.aaf4823
Rhee NA, Wahlgren CD, Pedersen J, Mortensen B, Langholz E, Wandall EP, Friis SU, Vilmann P, Paulsen SJ, Kristiansen VB, Jelsing J, Dalboge LS, Poulsen SS, Holst JJ, Vilsboll T, Knop FK (2015) Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia 58:2254–2258. https://doi.org/10.1007/s00125-015-3696-3
Roberts GP, Larraufie P, Richards P, Kay RG, Galvin SG, Miedzybrodzka EL, Leiter A, Li HJ, Glass LL, Ma MKL, Lam B, Yeo GSH, Scharfmann R, Chiarugi D, Hardwick RH, Reimann F, Gribble FM (2019) Comparison of human and murine enteroendocrine cells by transcriptomic and peptidomic profiling. Diabetes 68:1062–1072. https://doi.org/10.2337/db18-0883
Rudling M, Camilleri M, Graffner H, Holst JJ, Rikner L (2015) Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord 15:75. https://doi.org/10.1186/s12872-015-0070-9
Ryan DH (2021) Semaglutide for obesity: four STEPs forward, but more to come. Lancet Diabetes Endocrinol 9:252–254. https://doi.org/10.1016/S2213-8587(21)00081-4
Ryan GJ, Jobe LJ, Martin R (2005) Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 27:1500–1512. https://doi.org/10.1016/j.clinthera.2005.10.009
Salehi M, Gastaldelli A, D'Alessio DA (2014) Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 146:669–680.e2. https://doi.org/10.1053/j.gastro.2013.11.044
Samocha-Bonet D, Wong O, Synnott EL, Piyaratna N, Douglas A, Gribble FM, Holst JJ, Chisholm DJ, Greenfield JR (2011) Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. J Nutr 141:1233–1238. https://doi.org/10.3945/jn.111.139824
Sankyo D (2018) 12-Week study of DS-8500a in subjects with type 2 diabetes mellitus on metformin
Sanofi (2018) Form 20-F. https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Sanofi-20-F-2018-EN-PDF-e-accessible_02.pdf?la=en&hash=0E0CB0122FEDA3881B3857221DB9345A. Accessed 24 Jun 2021
Schiavon M, Visentin R, Gobel B, Riz M, Cobelli C, Klabunde T, Dalla Man C (2021) Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide. Diabetes Obes Metab. https://doi.org/10.1111/dom.14394
Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW, Holst JJ, Astrup A, Sjodin A (2014) Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab 306:E1248–E1256. https://doi.org/10.1152/ajpendo.00569.2013
Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA (1998) Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 15:485–491. https://doi.org/10.1002/(SICI)1096-9136(199806)15:6<485::AID-DIA610>3.0.CO;2-Y
Sorensen KV, Korfitzen SS, Kaspersen MH, Ulven ER, Ekberg JH, Bauer-Brandl A, Ulven T, Hojlund K (2021) Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans. Clin Nutr 40:2169–2179. https://doi.org/10.1016/j.clnu.2020.09.043
Sprecher U, Mohr P, Martin RE, Maerki HP, Sanchez RA, Binggeli A, Kunnecke B, Christ AD (2010) Novel, non-peptidic somatostatin receptor subtype 5 antagonists improve glucose tolerance in rodents. Regul Pept 159:19–27. https://doi.org/10.1016/j.regpep.2009.09.006
Svane MS, Jorgensen NB, Bojsen-Moller KN, Dirksen C, Nielsen S, Kristiansen VB, Torang S, Wewer Albrechtsen NJ, Rehfeld JF, Hartmann B, Madsbad S, Holst JJ (2016) Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. Int J Obes 40:1699–1706. https://doi.org/10.1038/ijo.2016.121
Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL (2005) Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146:3748–3756. https://doi.org/10.1210/en.2005-0473
Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167–177. https://doi.org/10.1016/j.cmet.2009.08.001
Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:364–371. https://doi.org/10.2337/db11-1019
Trevaskis JL, Sun C, Athanacio J, D'Souza L, Samant M, Tatarkiewicz K, Griffin PS, Wittmer C, Wang Y, Teng CH, Forood B, Parkes DG, Roth JD (2015) Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents. Diabetes Obes Metab 17:61–73. https://doi.org/10.1111/dom.12390
Tsakmaki A, Fonseca Pedro P, Pavlidis P, Hayee BH, Bewick GA (2020) ISX-9 manipulates endocrine progenitor fate revealing conserved intestinal lineages in mouse and human organoids. Mol Metab 34:157–173. https://doi.org/10.1016/j.molmet.2020.01.012
Ueno H, Ito R, Abe SI, Ookawara M, Miyashita H, Ogino H, Miyamoto Y, Yoshihara T, Kobayashi A, Tsujihata Y, Takeuchi K, Watanabe M, Yamada Y, Maekawa T, Nishigaki N, Moritoh Y (2019) SCO-267, a GPR40 full agonist, improves glycemic and body weight control in rat models of diabetes and obesity. J Pharmacol Exp Ther 370:172–181. https://doi.org/10.1124/jpet.118.255885
Unniappan S, McIntosh CH, Demuth HU, Heiser U, Wolf R, Kieffer TJ (2006) Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia 49:1915–1923. https://doi.org/10.1007/s00125-006-0310-8
van Nierop FS, Scheltema MJ, Eggink HM, Pols TW, Sonne DP, Knop FK, Soeters MR (2017) Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol 5:224–233. https://doi.org/10.1016/S2213-8587(16)30155-3
West JA, Tsakmaki A, Ghosh SS, Parkes DG, Gronlund RV, Pedersen PJ, Maggs D, Rajagopalan H, Bewick GA (2021) Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism. PLoS One 16:e0249239. https://doi.org/10.1371/journal.pone.0249239
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, Group SS (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989. https://doi.org/10.1056/NEJMoa2032183
Xu Y, Van Hul M, Suriano F, Preat V, Cani PD, Beloqui A (2020) Novel strategy for oral peptide delivery in incretin-based diabetes treatment. Gut 69:911–919. https://doi.org/10.1136/gutjnl-2019-319146
Yamada Y, Terauchi Y, Watada H, Nakatsuka Y, Shiosakai K, Washio T, Taguchi T (2018) Efficacy and safety of GPR119 agonist DS-8500a in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Adv Ther 35:367–381. https://doi.org/10.1007/s12325-018-0668-2
Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, Hashemi M, Adamo M, Finer N, Fiennes AG, Withers DJ, Batterham RL (2014) Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg 24:241–252. https://doi.org/10.1007/s11695-013-1066-0
Zhang Q, Delessa CT, Augustin R, Bakhti M, Collden G, Drucker DJ, Feuchtinger A, Caceres CG, Grandl G, Harger A, Herzig S, Hofmann S, Holleman CL, Jastroch M, Keipert S, Kleinert M, Knerr PJ, Kulaj K, Legutko B, Lickert H, Liu X, Luippold G, Lutter D, Malogajski E, Medina MT, Mowery SA, Blutke A, Perez-Tilve D, Salinno C, Sehrer L, DiMarchi RD, Tschop MH, Stemmer K, Finan B, Wolfrum C, Muller TD (2021) The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab 33:833–844.e5. https://doi.org/10.1016/j.cmet.2021.01.015
Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E, Investigators P (2019) Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care 42:2262–2271. https://doi.org/10.2337/dc19-0898
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Miedzybrodzka, E.L., Gribble, F.M., Reimann, F. (2022). Targeting the Enteroendocrine System for Treatment of Obesity. In: Eckel, J., Clément, K. (eds) From Obesity to Diabetes. Handbook of Experimental Pharmacology, vol 274. Springer, Cham. https://doi.org/10.1007/164_2022_583
Download citation
DOI: https://doi.org/10.1007/164_2022_583
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-99994-0
Online ISBN: 978-3-030-99995-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)